title: Cell recovery comparison between plasma depletion/reduction- and red cell reduction-processing of umbilical cord blood.
abstract: OBJECTIVE
  Limited cell dose has hampered the use of cord blood transplantation (CBT) in adults. One method of minimizing nucleated cell loss in cord blood (CB) processing is to deplete or reduce plasma but not red blood cells - plasma depletion/reduction (PDR).
  
  
  METHODS
  The nucleated cell loss of PDR was studied, and determined to be less than 0.1% in the discarded supernatant plasma fraction in validation experiments. After testing and archival sampling, the median nucleated cell recovery for PDR processing was 90%, and median CD34(+) cell recovery 88%. In a CB bank inventory of 12 339 products with both pre- and post-processing total nucleated cells (TNC), PDR processing resulted in median post-processing TNC recoveries of 90.0% after testing and archival samples removal. Using the same 10 CB units divided into two halves, we compared directly the recovery of PDR against hydroxyethyl starch red cell reduction (RCR) for TNC, CD34(+) cells and colony-forming units (CFU-GM, CFU-E, CFU-GEMM and total CFU) after parallel processing. We also compared the loss of very small embryonic-like stem cells (VSEL).
  
  
  RESULTS
  We demonstrated significantly higher recoveries using PDR for TNC (124%), CD34(+) cells (121%), CFU-GM (225%), CFU-GEMM (201%), total CFU (186%) and VSEL (187%). The proportion of high TNC products was compared between 10 912 PDR and 38 819 RCR CB products and found to be 200% higher for products that had TNC ≥150 × 10(7) (P = 0.0001) for the PDR inventory.
  
  
  CONCLUSIONS
  Our data indicate that PDR processing of CB provides a significantly more efficient usage of this valuable and scarce resource.
authors.affiliation: StemCyte International Cord Blood Center, Covina, California 91722, USA. rchow@stemcyte.com
authors.forename: Robert
authors.initials: R
authors.lastname: Chow
authors.forename: Allen
authors.initials: A
authors.lastname: Lin
authors.forename: Richard
authors.initials: R
authors.lastname: Tonai
authors.forename: Rafael
authors.initials: R
authors.lastname: Bolanos
authors.forename: Char
authors.initials: C
authors.lastname: Connor
authors.forename: Adrienne
authors.initials: A
authors.lastname: Mendoza
authors.forename: Rachelle
authors.initials: R
authors.lastname: Heminger
authors.forename: Michelle
authors.initials: M
authors.lastname: Chow
authors.forename: Eric
authors.initials: E
authors.lastname: Ho
authors.forename: Judy
authors.initials: J
authors.lastname: Kang
authors.forename: Laura
authors.initials: L
authors.lastname: Gindy
authors.forename: Chen
authors.initials: C
authors.lastname: Fu
authors.forename: Andrew
authors.initials: A
authors.lastname: Rao
authors.forename: Jeffrey F
authors.initials: JF
authors.lastname: Gau
authors.forename: Brian C
authors.initials: BC
authors.lastname: Wang
authors.forename: Izabela
authors.initials: I
authors.lastname: Klich
authors.forename: Janina
authors.initials: J
authors.lastname: Ratajczak
authors.forename: Mariusz
authors.initials: M
authors.lastname: Ratajczak
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Petz
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology / Q000378:metabolism*; D018952:Antigens, CD34 / Q000096:biosynthesis; D001771:Blood Banks; D002470:Cell Survival; D036101:Cord Blood Stem Cell Transplantation; D053595:Embryonic Stem Cells / Q000166:cytology / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism / Q000473:pathology; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000378:metabolism; D008962:Models, Theoretical; D010956:Plasmapheresis / Q000379:methods; D011247:Pregnancy; D044968:Regenerative Medicine / Q000379:methods; D013048:Specimen Handling
chemical_list: D018952:Antigens, CD34; D006895:Hydroxyethyl Starch Derivatives